Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.11-15 18:57

Sangamo Therapeutics (NASDAQ:SGMO) Third Quarter 2024 Results Key Financial Results Revenue: US$49.4m (up 426% from 3Q 2023). Net income: US$10.7m (up from US$104.2m loss in 3Q 2023). Profit margin: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483284329?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","is_english":true,"pubTime":"2024-11-15 18:57","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483284329","market":"us","top_or_hot":-1,"title":"Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations","media":"Simply Wall St.","content":"<div>\n<p>Sangamo Therapeutics (NASDAQ:SGMO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$49.4m (up 426% from 3Q 2023).\nNet income: US$10.7m (up from US$104.2m loss in 3Q 2023).\nProfit margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sangamo-therapeutics-third-quarter-2024-105724603.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sangamo-therapeutics-third-quarter-2024-105724603.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sangamo Therapeutics (NASDAQ:SGMO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$49.4m (up 426% from 3Q 2023).\nNet income: US$10.7m (up from US$104.2m loss in 3Q 2023).\nProfit margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sangamo-therapeutics-third-quarter-2024-105724603.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMO","symbol_name":"Sangamo Therapeutics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-third-quarter-2024-105724603.html","article_id":"2483284329","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483284329","pubTimestamp":1731668244,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Profit margin: 22% . The move to profitability was primarily driven by higher revenue.NasdaqCM:SGMO Earnings and Revenue Growth November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 97%. Earnings per share  also surpassed analyst estimates.Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 25% from a week ago.It's necessary to consider the ever-present spectre of investment risk.   We've identified 4 warning signs  with Sangamo Therapeutics , and understanding these should be part of your investment process.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SGMO":"Sangamo Therapeutics Inc","LENZ":"Therapeutics"},"translate_title":"Sangamo Therapeutics 2024年第三季度收益：超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SGMO":0.9},"content_text":"Sangamo Therapeutics (NASDAQ:SGMO) Third Quarter 2024 Results\nKey Financial Results\n\nRevenue: US$49.4m (up 426% from 3Q 2023).\nNet income: US$10.7m (up from US$104.2m loss in 3Q 2023).\nProfit margin: 22% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue.\nEPS: US$0.051 (up from US$0.59 loss in 3Q 2023).\n\n\n\n\n  NasdaqCM:SGMO Earnings and Revenue Growth November 15th 2024\n \n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\nSangamo Therapeutics Revenues and Earnings Beat Expectations\n Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) also surpassed analyst estimates. \n Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. \nPerformance of the American Biotechs industry.\n The company's shares are down 25% from a week ago. \nRisk Analysis\n It's necessary to consider the ever-present spectre of investment risk.   We've identified 4 warning signs  with Sangamo Therapeutics (at least 1 which is significant), and understanding these should be part of your investment process. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483284329"}